title: Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys.
abstract: Neointimal hyperplasia is a major cause of restenosis after coronary intervention. Because vascular injury is now recognized to involve an inflammatory response, monocyte chemoattractant protein-1 (MCP-1) might be involved in underlying mechanisms of restenosis. In the present study, we demonstrate the important role of MCP-1 in neointimal hyperplasia after cuff-induced arterial injury. In the first set of experiments, placement of a nonconstricting cuff around the femoral artery of intact mice and monkeys resulted in inflammation in the early stages and subsequent neointimal hyperplasia at the late stages. We transfected with an N-terminal deletion mutant of the human MCP-1 gene into skeletal muscles to block MCP-1 activity in vivo. This mutant MCP-1 works as a dominant-negative inhibitor of MCP-1. This strategy inhibited early vascular inflammation (monocyte infiltration, increased expression of MCP-1, and inflammatory cytokines) and late neointimal hyperplasia. In the second set of experiments, the cuff-induced neointimal hyperplasia was found to be less in CCR2-deficient mice than in control CCR2(+/+) mice. The MCP-1/CCR2 pathway plays a central role in the pathogenesis of neointimal hyperplasia in cuffed femoral artery of mice and monkeys. Therefore, the MCP-1/CCR2 pathway can be a therapeutic target for human restenosis after coronary intervention.
authors.affiliation: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. egashira@cardiol.med.kyushu-u.ac.jp
authors.forename: Kensuke
authors.initials: K
authors.lastname: Egashira
authors.forename: Qingwei
authors.initials: Q
authors.lastname: Zhao
authors.forename: Chu
authors.initials: C
authors.lastname: Kataoka
authors.forename: Kishou
authors.initials: K
authors.lastname: Ohtani
authors.forename: Makoto
authors.initials: M
authors.lastname: Usui
authors.forename: Israel F
authors.initials: IF
authors.lastname: Charo
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Nishida
authors.forename: Shujiro
authors.initials: S
authors.lastname: Inoue
authors.forename: Makoto
authors.initials: M
authors.lastname: Katoh
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Ichiki
authors.forename: Akira
authors.initials: A
authors.lastname: Takeshita
mesh_terms: D000818:Animals; D018932:Chemokine CCL2 / Q000097:blood / Q000235:genetics / Q000502:physiology*; D005263:Femoral Artery / Q000293:injuries* / Q000473:pathology; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010957:Plasmids / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013997:Time Factors; D014162:Transfection; D017539:Tunica Intima / Q000378:metabolism / Q000473:pathology*
chemical_list: C515334:CCR2 protein, human; C515335:Ccr2 protein, mouse; D018932:Chemokine CCL2; D012333:RNA, Messenger; D054390:Receptors, CCR2; D019707:Receptors, Chemokine